Who are Bromfenac Ophthalmic Solution A's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aspirin loading dose, Ibuprofen Acid, Diclofenac oral + Placebo Oral, ABS, Novel strategy Aspirin, Prednisone and Aspirin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bromfenac-ophthalmic-solution-a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bromfenac Ophthalmic Solution A — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bromfenac Ophthalmic Solution A (Bromfenac Ophthalmic Solution A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Ophthalmology.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Bromfenac Ophthalmic Solution A (Bromfenac Ophthalmic Solution A) — Bausch & Lomb Incorporated. Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Bromfenac Ophthalmic Solution A TARGET	Bromfenac Ophthalmic Solution A	Bausch & Lomb Incorporated	phase 3	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Aspirin loading dose	Aspirin loading dose	Icahn School of Medicine at Mount Sinai	marketed	Antiplatelet agent; nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Ibuprofen Acid	Ibuprofen Acid	Reckitt Benckiser Healthcare (UK) Limited	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Diclofenac oral + Placebo Oral	Diclofenac oral + Placebo Oral	Hospital de Clinicas de Porto Alegre	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
ABS	ABS	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
Novel strategy Aspirin	Novel strategy Aspirin	Assistance Publique - Hôpitaux de Paris	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Prednisone and Aspirin	Prednisone and Aspirin	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Corticosteroid and nonsteroidal anti-inflammatory drug (NSAID) combination	Glucocorticoid receptor (prednisone); Cyclooxygenase-1 and Cyclooxygenase-2 (aspirin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

Università degli Studi di Brescia · 4 drugs in this class
Bausch & Lomb Incorporated · 4 drugs in this class
Bayer · 3 drugs in this class
Pfizer · 3 drugs in this class
Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
Organon and Co · 3 drugs in this class
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
Bezmialem Vakif University · 2 drugs in this class
Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
Center For Excellence In Eye Care · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bromfenac Ophthalmic Solution A — Competitive Intelligence Brief. https://druglandscape.com/ci/bromfenac-ophthalmic-solution-a. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing